Project 1 will analyze pharmacokinetics of the prototypical carcinogenic polycyclic aromatic hydrocarbon (PAH), benzo[a]pyrene (BaP) in humans at environmentally relevant exposures. Currently, regulatory agencies (EPA, FDA) and ATSDR and lARC have to rely on high-dose animal studies for predicting safe lifetime exposure levels. Our overall hypothesis is that BaP, given to humans at levels encountered in the environment, will exhibit pharmacokinetics predictable from PBPK models constructed in mice. We further hypothesize that the relative potency factor (RPF) for humans exposed to PAH dietary mixtures will be predictive of risk.
The final aim i s exploratory and seeks to identify individuals with greater susceptibility based on a common genetic polymorphism. Human volunteers will be administered a dose of [14C]-BaP an order of magnitude lower than the average daily exposure of a U.S. non-smoker. The use of accelerator mass spectrometry (AMS) allows for micro-dosing of both chemical and radioisotope (5 nCi) and still follow blood and urine levels for three days. Use of newly developed AMS technology permits us to access the levels of parent BaP as well as individual metabolites, a major advance that will contribute to ask assessment. The EPA is currently considering the use of a relative potency factor (RPF) approach in risk assessment for PAH mixtures. We will conduct a study in which 1-3 ounces of smoked salmon containing ten times the BaPeq, based on the RPF of the PAHs in the salmon, will be co-administered with the [14C]- BaP. By examining pharmacokinetics, metabolite profiles and covalent DNA adducts in blood, we can provide the first test ever of the RPF approach in humans and at environmentally relevant levels. Finally, individuals that exhibit distinct BaP metabolite profiles or levels of BaP-DNA adducts will be genotyped for allelic variants of BaP-metabolizing enzymes in an exploratory gene-environment interaction study. These studies are highly innovative and significant and will markedly advance the field of risk assessment by providing a unique and powerful dataset on pharmacokinetic behavior of PAHs in humans exposed at environmental levels.

Public Health Relevance

PAHs are environmental contaminants prevelant at Superfund Sites and represent 3 top 10 most hazardous substances (ATSDR Priority List of Hazardous Substances). A major obstacle for regulator agencies is lack of human data. We will characterize uptake/elimination of BaP in humans at environmental levels and identify susceptible individuals. This provides critical data for health risk from environmental exposure to PAHs.

National Institute of Health (NIH)
National Institute of Environmental Health Sciences (NIEHS)
Hazardous Substances Basic Research Grants Program (NIEHS) (P42)
Project #
Application #
Study Section
Special Emphasis Panel ()
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Oregon State University
United States
Zip Code
Balik-Meisner, Michele; Truong, Lisa; Scholl, Elizabeth H et al. (2018) Elucidating Gene-by-Environment Interactions Associated with Differential Susceptibility to Chemical Exposure. Environ Health Perspect 126:067010
Geier, Mitra C; James Minick, D; Truong, Lisa et al. (2018) Systematic developmental neurotoxicity assessment of a representative PAH Superfund mixture using zebrafish. Toxicol Appl Pharmacol 354:115-125
Tan, Yu-Mei; Leonard, Jeremy A; Edwards, Stephen et al. (2018) Aggregate Exposure Pathways in Support of Risk Assessment. Curr Opin Toxicol 9:8-13
Titaley, Ivan A; Ogba, O Maduka; Chibwe, Leah et al. (2018) Automating data analysis for two-dimensional gas chromatography/time-of-flight mass spectrometry non-targeted analysis of comparative samples. J Chromatogr A 1541:57-62
Geier, Mitra C; Chlebowski, Anna C; Truong, Lisa et al. (2018) Comparative developmental toxicity of a comprehensive suite of polycyclic aromatic hydrocarbons. Arch Toxicol 92:571-586
Bugel, Sean M; Tanguay, Robert L (2018) Multidimensional chemobehavior analysis of flavonoids and neuroactive compounds in zebrafish. Toxicol Appl Pharmacol 344:23-34
Garcia, Gloria R; Bugel, Sean M; Truong, Lisa et al. (2018) AHR2 required for normal behavioral responses and proper development of the skeletal and reproductive systems in zebrafish. PLoS One 13:e0193484
Roper, Courtney; Simonich, Staci L Massey; Tanguay, Robert L (2018) Development of a high-throughput in vivo screening platform for particulate matter exposures. Environ Pollut 235:993-1005
Haggard, Derik E; Noyes, Pamela D; Waters, Katrina M et al. (2018) Transcriptomic and phenotypic profiling in developing zebrafish exposed to thyroid hormone receptor agonists. Reprod Toxicol 77:80-93
Hummel, Jessica M; Madeen, Erin P; Siddens, Lisbeth K et al. (2018) Pharmacokinetics of [14C]-Benzo[a]pyrene (BaP) in humans: Impact of Co-Administration of smoked salmon and BaP dietary restriction. Food Chem Toxicol 115:136-147

Showing the most recent 10 out of 174 publications